This app has been created exclusively for participants in the medical study for GSK BEconneCTD-ILD 221672 France. It contains Televisit functionality and allows participants to complete questionnaires.

A Phase 3, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of belimumab adminstered subcutaneously in adults with interstitial lung disease (ILD) associated with connected tissue disease (CTD).